Category: JCN Newswire

TOKYO, July 15, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. today announced the latest findings on etalanetug (development code: E2814) showed that this investigational anti-MTBR antibody reduced levels of plasma eMTBRtau243, a key biomarker of Alzheimer’s disease (AD) tau tangle pathology. The investigational compound etalanetug may have the potential to bind to the microtubule-binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology in the brain. Tau tangles are a hallmark of AD and are believed to be strongly associated with memory loss, cognitive decline, and disease progression.1 The findings were presented during the Featured Research Session, “Mechanisms Beyond Amyloid: Etalanetug Reduces Tau Tangle-Specific Plasma Biomarker eMTBR-tau243 in Dominantly Inherited Alzheimer’s Disease (DIAD),” at the Alzheimer’s Association International Conference® (AAIC®) 2026 in London and online.The highly sensitive blood biomarker assay measuring eMTBR-tau243 was developed as a potential alternative for cerebrospinal fluid (CSF) and Positron Emission Tomography (PET) testing. This analysis evaluated changes in plasma tau biomarkers following etalanetug administration and compared them with changes observed in CSF biomarkers in individuals with DIAD enrolled in the Phase Ib/II Study 103(NCT04971733).Key FindingsPlasma eMTBR-tau243 captures disease-specific pathological changes originating from taupathology in the brain- Etalanetug reduced CSF eMTBR-tau243 by 62% at three months and by 89% at nine months.- Etalanetug reduced plasma eMTBR-tau243 by 78% at 3 months and by more than 90% at 9 months,indicating that plasma eMTBR-tau243 closely mirrored disease-related changes captured in CSF.- Plasma phosphorylated tau (p-tau217, p-tau181, and p-tau231) and t-tau increased after etalanetug administration in both individuals with DIAD and healthy adults. This change is considered to be attributable to non-CNS tau species derived from peripheral tissues being stabilized by binding to etalanetug in plasma, thereby inhibiting their degradation.- Plasma eMTBR-tau243 was largely absent in healthy adults and detected only in patients with DIAD, suggesting it reflects disease-related tau pathology. Administration of etalanetug reduced levels of this biomarker.- These results suggest that plasma eMTBR-tau243, unlike plasma phosphorylated tau species and ttau, is a biomarker that captures disease-specific pathological changes originating from tau pathologyin the brain.Etalanetug acts on tau pathology in the brain, one of the underlying pathologies of AD- Etalanetug reduced multiple CSF phosphorylated tau species and t-tau in patients with DIAD. Among these, p-tau205 is a marker reflecting late-stage tau pathology (T2 biomarker) in the Alzheimer's Association guidelines. 2- These findings represent the first report of an anti-tau therapy reducing CSF p-tau205 in patients with DIAD.These results highlight that etalanetug acts on tau pathology in the brain, one of the underlying pathologies of AD. Plasma eMTBR-tau243 may serve as a practical, less invasive biomarker that captures AD-specific pathological changes and may play an important role in the future clinical development of etalanetug.* eMTBR-tau243 is a novel fluid biomarker consisting of tau fragments that include tau protein amino acid residue 243 and MTBR, with endogenous cleavage at the C-terminal side of residue 256. It is thought to arise during the formation of neurofibrillary tangles, a key pathological feature of AD, and a strong correlation has been shown between tau PET and eMTBR-tau243 in both plasma and CSF.3** DIAD: Dominantly Inherited Alzheimer’s disease (DIAD) is a rare form of AD that causes memory loss and dementia in individuals — typically while they are in their 30s to 50s. The disease affects less than 1% of the total population of people with Alzheimer’s disease.Media Inquiries:Public Relations DepartmentEisai Co., Ltd.+81-(0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+ 1-201-753-1945Libby_Holman@eisai.com About etalanetug (E2814)Etalanetug is an anti-MTBR (microtubule-binding region) tau antibody discovered through collaborative research between Eisai and University College London. It is designed to inhibit the propagation of tau seeds within the brain. Etalanetug is being developed as a potential disease-modifying therapy for tauopathies, including sporadic Alzheimer’s disease (AD).Currently, etalanetug is being evaluated in two ongoing clinical studies: the Tau NexGen Phase II/III trial indominantly inherited Alzheimer’s disease (DIAD), conducted under the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) and led by Washington University School of Medicine in St. Louis, added to the standard of-care anti-Aβ protofibril antibody lecanemab (brand name: LEQEMBI), and the Phase II Study 202, a global randomized trial in individuals with early sporadic AD, also assessing etalanetug added to lecanemab. In September 2025, etalanetug received Fast Track designation from the U.S. Food and Drug Administration (FDA).Phase 1b/2 Study 103 (NCT04971733)Phase 1b/2 Study 103 is an open-label study evaluating the safety, tolerability, and effects of etalanetug on tau-related biomarkers in cerebrospinal fluid (CSF) in participants with dominantly inherited Alzheimer's disease(DIAD). Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 15, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) has developed a first-of-its-kind technology (*1) that uses proprietary AI to rapidly generate highly detailed 3D models in as little as one minute, solely from footage captured with general-purpose cameras such as those on smartphones, while automatically removing unnecessary subjects. This technology was developed in collaboration with the Keio AI Research Center (*2).The technology can generate 3D models in as little as one minute that precisely replicate on-site conditions without the need for costly specialized equipment and without interrupting operations, even in frequently changing environments such as electric power infrastructure facilities and construction sites. Additionally, the 3D models can be easily viewed on ordinary computers or tablets, allowing users to instantly assess on-site conditions. This facilitates remote facility inspections and enables rapid decision-making in the event of anomalies.With this technology, NEC aims to promote the adoption of digital twin technology among infrastructure operators and the construction industry, helping to alleviate labor shortages and enhance facility safety. NEC plans to commercialize this technology within fiscal year 2027.BackgroundIn recent years, infrastructure operators and worksites in the construction industry have been facing labor shortages and rising travel costs associated with facility inspections. This has resulted in expanded efforts to share on-site footage with supervisors in remote locations to facilitate remote decision-making and guidance. However, relying solely on video feeds from sites makes it difficult to quickly identify specific scenes or viewpoints, posing challenges in accurately assessing on-site situations.In this context, as one method for creating digital twins—which replicate real-world on-site conditions in virtual spaces—there are high expectations for the use of 3D models that allow users to view the areas they wish to inspect from any viewpoint. Meanwhile, hurdles to adoption remain, including the need for costly specialized equipment, the halting of on-site operations for filming, and the considerable time required to generate 3D models after filming.To address these challenges, NEC combined Gaussian Splatting (*4), a technique that has recently attracted attention for its growing use in generating backgrounds for movies and animation, with its proprietary AI, achieving the rapid generation of highly detailed 3D models.Value provided by this technologyThis newly developed technology eliminates the need for costly specialized equipment and enables the rapid generation of highly detailed 3D models that precisely replicate on-site conditions without disrupting operations. Furthermore, the 3D models can be viewed on ordinary computers or tablets, allowing users to instantly assess on-site conditions. In addition to enabling remote facility inspections and facilitating rapid decision-making in the event of anomalies, this technology allows for the optimal allocation of limited personnel, which supports more efficient and advanced on-site operations.Features of this technology(1) Rapid generation of 3D models using efficient, optimized placement of pointsThe technology automatically analyzes the visual complexity of on-site video footage. In complex areas, the points forming the 3D model are densely clustered. In contrast, in more uniform areas, these points are more spaced out, optimizing the quantity and density of the points. This enables the generation of highly detailed 3D models while minimizing the total number of points required, all without sacrificing visual detail. Compared to conventional methods for generating Gaussian Splatting, this approach reduces the generation time by 90%, enabling rapid generation in as little as one minute.(2) High reproducibility of on-site conditions through automatic removal of unnecessary subjectsDuring the 3D model generation process, the technology automatically detects and removes temporary subjects that are visible in on-site footage. Additionally, since the background of the areas removed can be inferred and filled in based on the surrounding footage, accurate 3D models of on-site conditions that are free from unnecessary subjects can be generated even at sites in operation.Going forward, NEC remains committed to driving the adoption of digital twin technology among infrastructure operators, the construction industry, and beyond to alleviate personnel shortages, facilitate business transformation, and enhance facility safety.(*1) According to NEC research.(*2) Research conducted in collaboration with Professor Hideo Saito, a leading expert in the field of visual computing. https://www.keio.ac.jp/ja/org/kgri/research-centers/2026/A26-19/(Japanese text)(*3) Footage from the FM-Base(R) training and R&D center was used. FM-Base is a registered trademark of NEC Facilities, Ltd.(*4) Gaussian Splatting is a technique where spaces are depicted as clusters of scattered points with spatial extent. Lighter than their conventional counterparts, 3D models generated using Gaussian Splatting are known for their precise replication of colors and shapes. This allows for accurate 3D renderings of detailed shapes, layouts, and external appearances of equipment and machinery, as well as small parts like meters and buttons, while minimizing distortion and information loss.About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society. For more information, please visit https://www.nec.com, and follow us on LinkedIn and YouTube. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

London, July 15, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi Rail has been awarded the prestigious EcoVadis Platinum Medal, placing the company among the top 1% of businesses assessed globally by EcoVadis over the past 12 months.This recognition highlights the strength and maturity of Hitachi Rail’s sustainability management system and reflects the company’s continued commitment to responsible business practices, environmental stewardship, ethical conduct, and supply chain transparency.The EcoVadis Platinum Medal is the highest level of recognition granted by EcoVadis, one of the world’s most trusted providers of business sustainability ratings. The assessment evaluates companies across four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.“Sustainability is not an ambition alongside business – it is increasingly integrated into how business creates value. Achieving EcoVadis Platinum reflects the progress we are making in embedding sustainability into the way we operate, make decisions, and manage risk. It also reflects the commitment of colleagues across our business who are strengthening performance, building resilience, and creating value every day,” said Dr. Maiya Shibasaki, Chief Sustainability Officer. As a global leader in sustainable transportation solutions, Hitachi Rail continues to invest in innovation that supports the transition to low-carbon mobility, helping cities and regions reduce emissions while improving connectivity and quality of life.The Platinum Medal also underscores Hitachi Rail’s commitment to transparency and responsible practices across its value chain. By working closely with suppliers and stakeholders, the company promotes high sustainability standards throughout its operations and business relationships, reinforcing its ambition to contribute to a more sustainable future through innovative rail technologies, digital solutions, and environmentally responsible transportation systems.About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi aims to be a global leader in continuously transforming social infrastructure through digital, contributing to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates worldwide across four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – as well as a Strategic SIB Business Unit focused on new growth areas. With Lumada at its core, Hitachi creates value by combining data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2025 (ended March 31, 2026) totaled 10,586.7 billion yen, with 606 consolidated subsidiaries and approximately 290,000 employees worldwide. Visit us at www.hitachi.com.About LumadaAbout Hitachi RailHitachi Rail is committed to driving the transition to sustainable mobility and has a clear focus on partnering with customers to rethink mobility. Its mission is to help every passenger, customer, and community enjoy the benefits of more connected, smooth, and sustainable transportation. With a turnover of more than €7 billion and 24,000 employees in more than 50 countries, Hitachi Rail is a reliable partner for the world's best transport companies. The company's presence is global, but the company is local, with success based on developing local talent and investing in people and communities. Its international expertise and experience covers every part of urban ecosystems, main lines and freight railways, from high-quality production and maintenance of rolling stock to digital signaling, payment systems and smart operations. Hitachi Rail, famous for Japan's iconic high-speed train, leverages the digital and artificial intelligence expertise of Hitachi Group companies to accelerate innovation and develop new technologies. For more information, visit hitachirail.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 15, 2026 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station, an exhibition center for Japanese anime operated by the Tokyo Metropolitan Government and the Association of Japanese Animations, is a facility that promotes the appeal of Japanese anime to the world under the motto “Making ANIME more interesting, Bringing ANIME far into the future.” Since opening in October 2023, the facility has welcomed numerous visitors from Japan and overseas, and on June 20, 2026, the number of visitors reached 300,000.The 300,000th visitors marking this milestone were a pair of guests. To commemorate surpassing 300,000 visitors, they were presented with anime goods sold at the goods store on the second floor, and they shared their surprise and delight: “I’m so happy—I never imagined I would be the 300,000th visitor!” When asked about which exhibits left an impression on them, they commented, “I’ve been watching BLEACH since I was little, and today I got to experience ‘Bankai’ through the digital content on the second floor. It’s amazing that you can experience all this for free.”Anime Tokyo Station preserves approximately 50,000 valuable materials related to past anime production processes on the first basement floor. The facility also exhibits the production process for traditional hand-drawn animation prior to the use of digital methods, introducing the production tools used at the time and materials created during the production process. In addition, special exhibitions on popular anime are held regularly on the second floor, introducing works currently being broadcast as well as titles that are attracting attention overseas.As a facility where a variety of people such as travelers visiting Tokyo from all over the world can discover both classic masterpieces and the latest popular series, and enjoy the appeal of anime from a variety of perspectives, Anime Tokyo Station will continue to share the appeal of anime and Tokyo with a wide range of anime fans both in Japan and overseas.Exhibit Currently Being Held- Second floorTV Anime “BLEACH: THE BLOOD WARFARE - The Calamity” Special Exhibition (until August 16, 2026)©K/STDPMore information: https://animetokyo.jp/en/archives/events/events75/- First basement floor“ChaO” Special Exhibition (until July 31, 2026)©2025 ChaO Production CommitteeMore information: https://animetokyo.jp/en/archives/events/events76/Venue OverviewName:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. / Special exhibitions close: 6:30 p.m.)Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/SNS：X｜https://x.com/animetokyo_info (@animetokyo_info)Instagram｜https://www.instagram.com/animetokyostation/(@animetokyostation)YouTube｜https://www.youtube.com/channel/UCSJOjGJE5Yiqw3PZ97AVdJw Inquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/files/20260715.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

KAWASAKI, Japan, July 14, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced the Japan launch of the Fujitsu AI-driven Modernization Service. Available from today, the service is designed to support the sustainable growth of businesses and organizations, and combines Fujitsu's practical modernization expertise cultivated through decades of system integration with generative AI. By leveraging multiple AI models and the expertise of specialized engineers, the service automates and optimizes modernization initiatives centered on rewrite and rehost approaches. The service supports customers’ modernization efforts rapidly and efficiently, and can shorten migration periods by approximately 40%.In recent years, with the acceleration of digital transformation (DX) and AI transformation (AX) in enterprises, the modernization of underlying legacy systems has become an urgent issue for strengthening competitiveness and responding quickly to environmental changes. This is particularly critical in sectors such as finance, public services, and healthcare, where legal revisions are frequent. Similarly, manufacturing and distribution industries, which require complex operational management, have accumulated years of operational know-how in legacy systems.To address these challenges, this service combines Fujitsu's proprietary AI platform Fujitsu Kozuchi and the Takane large language model (LLM) [1], with cutting-edge AI technologies such as Anthropic PBC's Claude and OpenAI's GPT. It also integrates the practical knowledge of Fujitsu's specialized engineers, Modernization Meisters, who are deeply familiar with legacy technologies. This fusion enables speedy and high-quality modernization, supporting customers' rapid business transformation.Through the provision of this service, Fujitsu will help various customers establish leadership in data utilization and contribute to the realization of rapid data-driven management decisions.Features of the Service1. Accelerating modernization through AI-driven automationAs core information for modernization, the service uses AI to comprehensively analyze various data from target legacy assets and centrally manages them as AI-ready structured data through Fujitsu’s proprietary AI technology. By establishing consistent decision-making criteria across modernization phases, the service minimizes rework and quality variations. Furthermore, it enables flexible adaptation to future expansion while preserving the value of existing system assets.The service also enables large-scale, efficient code conversion by leveraging proprietary AI agents developed specifically for modernization automation. These agents orchestrate workflows and execute tasks in parallel, while harness engineering automates language conversion and verification, and loop engineering continuously improves conversion outcomes. Rather than performing simple mechanical code conversion, the service enables migration to maintainable and extensible Java applications based on object-oriented principles. In addition, a human-in-the-loop approach provides final review and supplementation by experienced engineers, ensuring both consistent quality and effective risk mitigation. Together, these capabilities support large-scale, complex modernization projects while reducing project timelines by approximately 40%.2. Promoting customer DX with multi-AI modernization that optimally utilizes multiple AIsAt the core of the service are Fujitsu Kozuchi and the Takane LLM, combined with self-evolving multi-AI agent technology in which multiple AI agents collaborate to execute tasks and learn autonomously.In addition to Fujitsu's development technologies, the service actively utilizes world-leading AI technologies such as Anthropic's Claude and OpenAI's GPT. These technologies are flexibly combined and provided as a transformation service according to customer business needs, program characteristics, and security levels. This allows customers to focus on their core initiatives, such as business transformation and ROI (Return On Investment) generation, without requiring them to focus on the optimal selection and operational burden of rapidly evolving AI technologies, thereby steadily promoting modernization.3. Achieving high-speed and high-precision modernization with dedicated AI agents trained on Fujitsu's unique knowledgeSpecialized AI agents are trained on data from thousands of projects implemented by Fujitsu over many years, as well as success stories, and failure cases, which have been recorded and digitized as knowledge. This enables Japan-originated modernization with high reproducibility, reliability, and certainty, regardless of location and time, addressing the challenge of securing knowledge engineers in modernization, and accelerating its deployment.4. Sequentially providing self-service platforms to support customers' own AI utilizationAs the first phase of its AI modernization platform services, Fujitsu launched Fujitsu Application Transform powered by Fujitsu Kozuchi, an automated design document generation service, in March 2026. This newly launched Fujitsu AI-driven Modernization Service is specifically designed for modernization. Fujitsu optimally selects and adopts the latest AI technologies and provides them as a transformation service to customers. Fujitsu will sequentially provide AI service platforms that enable customers to perform modernization themselves, maximizing the practical knowledge gained from this service. Through the continued provision of this service, Fujitsu will support further acceleration and sustainable evolution of customers' modernization efforts.Figure: Overview of Fujitsu AI-driven Modernization Service[1] Takane LLMA large language model jointly developed by Fujitsu and Cohere Inc.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 100,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.5 trillion yen (US$23 billion) for the fiscal year ended March 31, 2026 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic, Investor and Analyst Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 14, 2026 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station is an anime exhibition site focused on Japanese anime content, which has developed a devout fan base around the world. From May 30, 2026 to August 16, 2026, it will be holding the TV Anime “BLEACH: THE BLOOD WARFARE - The Calamity” Special Exhibition. A sneak preview was held for the press on May 29, the day before the exhibition opened.©K/STDPThis special exhibition will feature past key visuals from the TV animation series “BLEACH: Thousand-Year Blood War,” as well as life-size character panels and a full-scale replica of the Zanpakuto “Zangetsu.” Additionally, visitors can relive the story through panels showcasing scenes from “Thousand-Year Blood War.” The exhibition will also feature the exhibition’s original digital content that allows visitors to experience the world of Bankai. The entire exhibition is designed to let visitors enjoy the charm and worldbuilding of the series with an immersive experience.Please visit Tokyo Anime Station and enjoy the thrilling worldbuilding and exhibits of the TV animation series “BLEACH: Thousand-Year Blood War.”Exhibits©K/STDPAbout the SeriesWhat is “BLEACH”?BLEACH is a smash-hit, sword-battle action manga by Tite Kubo that was serialized in Weekly Shonen Jump. Even after its conclusion, the series continues to enjoy enduring popularity worldwide, with over 130 million copies sold. The animated TV series, which began airing in October 2004, has produced over 360 episodes to date, along with four feature films.The final arc, Thousand-Year Blood War, premiered in October 2022 on TV TOKYO and other networks. The final part, BLEACH: Thousand-Year Blood War – The Calamity, is scheduled to be broadcast on July 25th 2026.TV animation series “BLEACH: Thousand-Year Blood War” Official Website: https://bleach-anime.com/en/Official X: @BLEACHanimationOfficial Instagram: @bleach_official_animeOfficial TikTok: @bleach.officialEvent OverviewTitle:TV Anime “BLEACH: THE BLOOD WARFARE - The Calamity” Special ExhibitionDates:May 30, 2026 to August 16, 2026Name:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. / Special exhibitions close: 6:30 p.m.)Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/SNS：X｜https://x.com/animetokyo_info (@animetokyo_info)Instagram｜https://www.instagram.com/animetokyostation/(@animetokyostation)YouTube｜https://www.youtube.com/channel/UCSJOjGJE5Yiqw3PZ97AVdJw Inquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp PDF: https://www.acnnewswire.com/docs/files/20260714.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 14, 2026 - (JCN Newswire via SeaPRwire.com) - JCB Co., Ltd. (Head Office: Minato-ku, Tokyo; Takayoshi Futae, Chairman and CEO; hereinafter "JCB") hereby announces that it has signed a memorandum of understanding (MOU) with an affiliate of Circle Internet Group, Inc. (“Circle”) (NYSE:CRCL), to explore collaboration utilizing stablecoins.Under this MOU, JCB and Circle will explore collaboration opportunities that combine Circle’s stablecoin payment infrastructure with JCB's global merchant network to advance cross-border payments and develop new payment experiences for merchants and customers.Background of the MOUStablecoins are gaining attention around the world as a foundation for creating a new ecosystem in cashless societies, given their high level of convenience, and the market is expanding rapidly. In particular, the use of stablecoins in payments is expected to bring a wide range of benefits, including reducing the burden of currency exchange for inbound tourists, further improving the efficiency of fund settlement, and improving cash flow for merchants.Against this backdrop, Circle has developed a full suite of stablecoin and blockchain infrastructure including USDC, EURC, Gateway and Arc, designed to support next-generation payment and settlement applications.As a global payments company, JCB is actively exploring new technologies that can enhance payment experiences for consumers and merchants while improving the efficiency of payment infrastructure.The MOU establishes a framework for ongoing collaboration between JCB and Circle, as they evaluate the application of stablecoin-enabled payment infrastructure across global payment use cases.Collaboration topics under considerationUnder the agreement, the two companies will primarily explore collaboration in the following areas:1. Cross-border treasury and paymentsBy utilizing USDC, the companies will explore opportunities to enhance cross-border treasury operations and payments. Initial efforts will include a proof of concept (PoC) focused on JCB’s internal fund transfers. The companies will evaluate opportunities to improve payment efficiency, reduce remittance costs, and support broader cross-border payment flows.2. Stablecoin-enabled payments at merchants in JapanThe companies will explore in-store stablecoin payment experiences for merchants and international visitors to Japan, while evaluating technologies that support interoperability and seamless payment experiences across multiple blockchain networks.Beyond these initial areas of exploration, JCB and Circle will continue to evaluate additional opportunities for collaboration that leverage stablecoin infrastructure to deliver new payment experiences for consumers and merchants.JCB’s Initiatives to Bring Stablecoin Payments into Practical Use in JapanIn January 2026, JCB also began collaboration with Digital Garage, Inc. ("Digital Garage") and Resona Holdings, Inc. ("Resona HD") toward the real-world implementation of stablecoin payments (*). In that collaboration, with Digital Garage as a partner, JCB has been identifying issues and examining solutions for enabling stablecoin payments at merchants in Japan through a proof of concept for stablecoin payments at physical stores.Through collaboration with Circle, Digital Garage, Resona HD, and other companies, JCB will contribute to the real-world implementation of stablecoin payments in Japan and overseas, as well as to the creation of a new payments ecosystem.(*) Press release dated January 16, 2026: "JCB, Digital Garage, and Resona Holdings Begin Collaboration Toward the Real-World Implementation of Stablecoin Payments"https://www.global.jcb/ja/press/2026/202601161100_others.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Contract Signing Ceremony with Local EPC Company in Riyadh, Saudi ArabiaTOKYO, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Power, a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI), has received orders to supply key boiler components for a project converting existing heavy oil-fired boilers at large-scale thermal power plants in Saudi Arabia into dual-fuel boilers capable of switching between and co-firing both natural gas and heavy oil. This contract was signed between Dar Al Balad Contracting and Operations (DAB), a local EPC (engineering, procurement, and construction) company, and Mitsubishi Corporation Machinery, as authorized agent of Mitsubishi Power. Leveraging its technical capabilities as the OEM (original equipment manufacturer) responsible for the design and manufacture of the existing boilers, Mitsubishi Power supports Saudi Arabia's energy policy to transition fuel sources in power generation and contributes to reducing the country's CO2 emissions.The targeted thermal power plants are the Jeddah South Power Plant and the Shuqaiq Power Plant, both located on Saudi Arabia's west coast. Each plant has a capacity of approximately 2.9 GW and consists of four units (Units 1 to 4). Operations began sequentially in 2017. Mitsubishi Power originally supplied the existing boilers component as the OEM at the time of plant construction and will utilize these existing assets to carry out the boiler supply work for the fuel conversion.The fuel conversion project is progressing under Saudi Arabia's energy policy, with the end customer being Saudi Energy (SE). Through its long-standing local partner DAB, Mitsubishi Power will support the conversion of the existing heavy oil-fired boilers into dual-fuel boilers, providing technical assistance to ensure the long-term stable operation of the plants.Saudi Arabia is advancing a shift in its power generation fuel mix from heavy oil to natural gas under the national strategy "Saudi Vision 2030," aiming to increase the share of natural gas-fired power generation to over 50%. The government has directed domestic power producers, including SE, to commence operations using natural gas, accelerating fuel conversion plans at power plants nationwide.Particularly on the west coast, where the ratio of heavy oil-fired power generation is high, there is strong demand for electricity. Fuel conversion from heavy oil to natural gas at existing power plants is essential to simultaneously maintain stable electricity supply and meet environmental requirements.Commenting on the contract award, Makoto Fujita, Senior General Manager, Steam Power Business Division, Energy Systems at MHI, said, "The Jeddah South and Shuqaiq power plants have played a vital role in ensuring a stable electricity supply on Saudi Arabia's west coast. As the OEM of the existing boilers, we are very proud to contribute to the country's energy transition and CO2 emissions reduction through our participation in this fuel conversion project. We will dedicate ourselves to the successful completion of this project and continue to provide support for the long-term stable operation of the plants."Mitsubishi Power will further strengthen its efforts to promote the widespread adoption of high-performance and reliable technologies, contributing to the stable supply of electric power essential for economic development worldwide, while supporting global environmental conservation through the advancement of low-carbon and decarbonized energy solutions and the modernization of existing power generation assets.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

KAWASAKI, Japan, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced that it will begin a field trial of an AI agent developed jointly with AEON Food Style Co., Ltd. (AEON Food Style), to autonomously support store operations under its Uvance for Retail initiative, which aims for sustainable growth in the retail industry through Data & AI. The trial will take place at a physical store in July 2026. This AI agent is designed to support store strategy formulation and sales floor layout planning, and the trial will verify its effectiveness in accelerating decision-making, standardizing operations, and improving efficiency in store management. Moving forward, Fujitsu will leverage the results of this field trial to further enhance store operations and management for AEON Food Style.BackgroundThe retail industry faces challenges such as chronic labor shortages, and store manager responsibilities, in particular, are diverse and heavily reliant on individual experience and skills, leading to issues of task expertise residing with specific individuals. AEON Food Style was established on March 1, 2026, through the integration of MaxValu Kanto, Daiei's Kanto operations, and AEON Market. Amid a declining population and diversifying consumer needs, AEON Food Style decided to promote the utilization of AI agents in collaboration with Fujitsu to support store managers in making swift decisions and executing strategic store operations, thereby realizing consistent, higher-quality service across all stores.OverviewIn developing this AI agent, Fujitsu's Forward Deployed Engineers (FDEs) and designers identified common tasks across the integrated companies' store operations and clarified the ideal store manager profile for AEON Food Style. Based on this, they formulated an optimal operational process (business model) for store management. Within approximately 10 days, four AI agent prototypes were developed to assist store managers in tasks where they felt a strong need for support, such as store strategy formulation, shelf layout planning, feasibility studies for initiatives, and trade area analysis. This field trial will focus on two of these AI agents.Trial Period: Expected to be several days in July 2026Targeted operations and verification content1. Store strategy formulationThe AI agent supports the execution of analysis based on the 3C's framework and the formulation of medium- to long-term store strategies. This trial will verify its effectiveness by measuring the reduction in the time store managers spend on strategy formulation and the adoption rate of AI agent-generated plans. Additionally, it will verify the agent's effectiveness in training new store managers following personnel changes and standardizing practical operations.2. Shelf allocation and layout planningThe AI agent generates detailed shelf plans and layout images based on headquarters' display instructions, product information, and store characteristics. This trial will verify the efficiency improvements in tasks from shelf plan creation to instructing sales floor personnel, as well as the effectiveness of smooth communication through sharing layout images.Figure: AI agent for shelf allocation and sales floor layout supportFuture PlansMoving forward, based on the results of this field trial, Fujitsu will collaborate with AEON Food Style to improve the accuracy and expand the application scope of the AI agent. Fujitsu will also consider further trials of AI agents aimed at increasing sales.Fujitsu aims to develop multi-AI agents for the retail industry, where multiple AI agents, including the store manager support AI agent, collaborate to autonomously execute tasks. Through Uvance for Retail, Fujitsu will drive innovation in the experiences of consumers and workers, thereby enhancing the retail industry's competitiveness and promoting sustainable growth.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 100,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.5 trillion yen (US$23 billion) for the fiscal year ended March 31, 2026 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu Press ContactsFujitsu LimitedPublic, Investor and Analyst Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)announced today that new data presented at the Alzheimer’s Association International Conference®(AAIC®) 2026 in London support that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI)formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer’s disease (AD). The data was featured during the “Lecanemab Subcutaneous Formulation in Early Alzheimer’s Disease: Emerging Clinical Evidence and Practical Use Considerations” Developing Topics Session #1-32-FRS-C.AD is a chronic, progressive disease that requires ongoing treatment. LEQEMBI is an early AD treatment that targets the underlying pathology of the disease, helping to slow cognitive decline and loss of daily functioning. The lecanemab subcutaneous auto-injector (SC-AI) was developed to provide a more convenient alternative to intravenous (IV) dosing from the initiation of treatment.Key FindingsThis session presented data from the lecanemab SC-AI development program in early Alzheimer’s disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience findings. Results showed that once-weekly 500 mg SC-AI achieved drug exposure similar to the approved intravenous (IV) initiation regimen (10 mg/kg every two weeks), supporting the expectation of similar clinical efficacy and safety, independent of the route of administration. The subcutaneous dosing option may offer a convenient at-home alternative to IV infusion which could support access and delivery of care across healthcare settings.Data ShowedBioequivalence Achieved: Once-weekly 500 mg SC-AI demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks), with an exposure ratio of 104% (90% confidence interval [CI]: 99.1%–109%). Exposure remained consistent across body weight quartiles, demonstrating a stable pharmacokinetic profile in a broad patient population.Efficacy Driven by Exposure, Not Route of Administration: Amyloid removal measured by amyloid PET, clinical efficacy measured by CDR-SB, and the incidence of ARIA-E were driven by lecanemab exposure rather than route of administration. The 500 mg SC-AI initiation regimen achieved exposure comparable to the IV initiation regimen, supporting the expectation of acomparable efficacy and safety profile despite the different route of administration.Consistent Results Across Patient Populations: The 500 mg SC-AI initiation regimen demonstrated consistent exposure, amyloid clearance as measured by amyloid PET, clinical efficacy and safety across body weight groups. In addition, amyloid clearance and clinical outcomes were not meaningfully affected by body weight, supporting the appropriateness of a fixed-dose regimen.Flexible switching between IV and SC administration: Patients may also switch from IV to SC administration, or vice versa, and if a dose is missed patients can take it the next day or up to day six providing greater convenience and flexibility in LEQEMBI administration.Safety Profile Aligned of SC LEQEMBIOverall safety profile of SC-AI was generally consistent with that observed for the IV formulation.Incidence of ARIA-E with the 500 mg SC-AI initiation regimen was predicted to be similar to that observed with the IV initiation regimen. Injection-related reactions were observed with subcutaneous LEQEMBI, most of which were localized, while systemic reactions were less frequently observed.The incidence of anti-drug antibodies (ADA) was low, at 1.4% in the 500 mg SC-AI group. No neutralizing antibodies were observed, confirming that the low immunogenicity profile was maintained with the SC-AI formulation.Clinical Trial Perspectives and Real-World Evidence: Sustained Clinical Benefit with SC-AIData from two U.S. Alzheimer’s treatment centers (Alzheimer’s Research and Treatment Center,and First Choice Neurology and Visionary Investigators Network) provide early insight into clinical trial and real-world use of subcutaneous LEQEMBI:At Alzheimer’s Research and Treatment Center, 28 patients receiving SC administration demonstrated slower cognitive decline as measured by CDR-SB over 36 months relative to a matched Alzheimer’s Disease Neuroimaging Initiative (ADNI) natural history cohort. The cohort included 25 patients newly initiated on SC administration and 3 patients who transitioned from IV administration.In a separate case series from First Choice Neurology and Visionary Investigators Network, 10 of 11 evaluable patients (91%) showed improvement or remained stable on MMSE compared with baseline before maintenance therapy. At this center, patients who had received maintenance therapy with SC administration for at least 6 months were included in the analysis.Patient and care partner surveys in these two sites demonstrated high satisfaction with subcutaneous LEQEMBI administration, with satisfaction rates ranging from 75% to 97%, convenience ratings from 83% to 97%, and willingness to recommend treatment ranging from 92% to 100%.Results presented in this session further reinforce the importance of early and continuous treatment, highlighting how LEQEMBI SC initiation and maintenance administration provides greater optionality for long-term disease management. Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisaiand Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1201-753-1945Libby_Holman@eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+1-781-464-2442IR@biogen.comFor more information: https://www.eisai.com/news/2026/pdf/enews202638pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

DALLAS, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi Digital Services today announced it has partnered with ServiceNow (NYSE: NOW), the AI control tower for business reinvention, to strengthen reliable and efficient management of mission critical infrastructure. Through this collaboration, the companies will advance Hitachi Intelligent Infrastructure Monitoring (HIIM) — an AI-driven solution that provides real-time monitoring and remote inspection while enabling a coordinated response across complex operations environments. As part of the broader partnership ecosystem, this collaboration leverages Hitachi Digital Services’ deep operational technology(OT) domain knowledge along with its physical AI and systems integration expertise to help customers connect operational data and enterprise workflows on the ServiceNow AI Platform, enabling teams to act on insights at scale.The combined HIIM and ServiceNow platform supports the vision of HMAX by Hitachi for intelligent solutions that safeguard and enable efficient operations of critical infrastructure. HMAX is a suite of next-generation solutions that brings the power of AI to social infrastructure with capabilities that optimize planning, prediction, and prevention via combined asset intelligence, digital services, and expert support for lifetime infrastructure management. Collectively, such innovations support Hitachi’s mission of tackling the most complex social infrastructure challenges to maximize outcomes and value for clients and society.Mission-critical infrastructure operators across the energy, mobility and manufacturing sectors face increasing pressure to maintain safety, reliability, and performance amid workforce constraints and operational demands. Operator requirements are made even more challenging when considering the often-disparate systems and subsequent siloed data sources needed to inform necessary, prompt decisions. Further, many organizations are unable to put operations data into action consistently across teams and systems in real time.“The organizations winning with AI aren't the ones with the most data. They're the ones who can act on it, across teams, in real time, with governance built in. Hitachi Digital Services brings the domain depth to understand what matters in mission-critical environments. ServiceNow provides the platform to turn that expertise into autonomous action, at scale," said Chris Bedi, ServiceNow chief customer officer and enterprise AI advisor. “For joint customers in energy, manufacturing, and mobility, closing that gap means moving from reactive response to autonomous resolution. As a result, our customers can expect to reduce risk, protect workers, and keep operations running.”A manufacturer-agnostic technology, HIIM integrates data sourced from video, thermal imaging, IoT sensors, and advanced analytics to deliver continuous visibility into infrastructure health. When combined with ServiceNow Workflow Data Fabric, analytics, and AI-driven workflows, HIIM extends beyond data visibility to drive automated enterprise-wide action that allows operations to: Compile data from multiple fragmented sources in real timeConvert compiled data into automated workflowsDetect, prioritize, and respond to issues proactively and with speedSeamlessly connect operations and enterprise teams to accelerate resolution and reduce risk“Hitachi Digital Services and the ServiceNow AI Platform combine industry depth with AI-powered enterprise workflow automation to further eliminate the disconnect between field operations and enterprise systems. The outcome is a real-time, connected operating model that turns insight into action at scale. In mission-critical environments — where delays, failures, and worker safety risks can have significant operational and business consequences — this capability is indispensable. It’s a level of innovation only made possible by this strong partnership,” said Srini Shankar, CEO of Hitachi Digital Services and President and CEO of GlobalLogic.Related LinksHIIM and ServiceNowHMAX by HitachiTrademark NoticeAll trademarks and product names are the property of their respective owners.About Hitachi Digital ServicesHitachi Digital Services, a wholly owned subsidiary of Hitachi, Ltd., is a global systems integrator powering mission critical platforms with people and technology. We help enterprises build, integrate, and run physical and digital systems with tailored solutions in cloud, data, IoT, and ERP modernization, underpinned by advanced AI. By combining Information Technology and Operational Technology (ITxOT), we drive efficiency, innovation, and growth across industries. With over 110 years of Hitachi Group’s engineering and technology leadership, Hitachi Digital Services is powering smarter platforms for a safer, more sustainable future. For more information on Hitachi Digital Services, please visit the company’s website at www.hitachids.com. About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi aims to be a global leader in continuously transforming social infrastructure through digital, contributing to aharmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates worldwide across four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – as well as a Strategic SIB Business Unit focused on new growth areas. With Lumada at its core, Hitachi creates value by combining data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2025 (ended March 31, 2026) totaled 10,586.7 billion yen, with 606 consolidated subsidiaries and approximately 290,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has demonstrated measurable improvement in Power Usage Effectiveness (PUE)(1) at an operational data center, reducing cooling energy consumption while maintaining stable operation. The project was conducted at the Fujitsu AKASHI Data Center operated by Fujitsu Limited, using existing multi—vendor infrastructure (a mix of equipment from multiple manufacturers).While traditional optimization focuses on individual equipment, this demonstration applied holistic control across the entire cooling system, including shared cooling infrastructure(2) and air handling units (AHUs) in server rooms. This system—level approach unlocks new energy savings potential and provides a scalable pathway to improve efficiency in existing data centers.Data center cooling system (Fujitsu AKASHI Data Center)(3)Addressing a Critical Industry ChallengeWith global data center demand surging, energy consumption has become a key constraint. Cooling systems alone account for over 60% of non—IT electricity use(4). Existing facilities prioritize operational stability when controlling cooling systems, making it difficult to incorporate energy optimization as a parallel priority. Further, the increase in AI workloads (the heavy computational processes required to run AI) has made operational requirements more demanding, limiting the effectiveness of existing energy—saving methods, especially those with multi—vendor setups.Demonstration Highlights and ResultsA key differentiator of this project was deployment without service interruption. Leveraging vendor agnostic cooling system optimization technology developed by MHI's Research & Innovation Center, MHI conducted simulations and demonstrated optimized control.Temperature distribution in the server room was identified as a key bottleneck, and rebalancing of airflow by managing air conditioning units improves the temperature distribution by 2℃ in return providing substantial headroom for optimizing other cooling systems. By fine—tuning the operation points of shared cooling infrastructure based on simulations and maintaining cooling water at an appropriate temperature, the project delivered a 2.3% energy reduction across the entire cooling system. In addition, the energy efficiency (COP)(5) of the centrifugal chillers increased by more than 1.2 points.This demonstration project was conducted in just one of the several server rooms in the data center. When the scope is scaled across all the server rooms, cooling system energy savings are projected to reach 7.6%, significantly enhancing overall PUE.Demonstration results and future potential"Operational data centers need to improve energy efficiency while utilizing existing equipment," said Shoji Yamasaki, General Manager, Data Center & Energy Management Department at MHI. "This demonstration proves that system—level cooling optimization—especially in multi—vendor environments—can deliver tangible results under real operating conditions."Going forward, MHI will further expand this approach, integrating decarbonized energy, resilient power systems, high—efficiency cooling, and advanced digital solutions to support sustainable and reliable data center operations worldwide.(1) Power Usage Effectiveness (PUE) is an indicator of how efficiently a data center uses power. The closer to 1.0, the greater the efficiency.(2) Shared Cooling infrastructure comprises equipment for cooling the entire data center, including cooling towers, cooling water pumps, chilled water pumps, and centrifugal chillers.(3) The "header" in the diagram is the main piping system that consolidates and distributes multiple systems of chilled and cooling water, enhancing stable supply and controllability. The "buffer tank" temporarily stores chilled or cooling water, absorbing fluctuations in flow rate and pressure to support stable operation of equipment. A UPS (Uninterruptible Power Supply) ensures a continuous supply of power in case of outages or under abnormal power conditions.(4) Figures from the International Energy Agency (IEA). For details, see the IEA website.https://www.iea.org/data-and-statistics/charts/share-of-electricity-consumption-by-data-centre-and-equipment-type-2024(5) Coefficient of Performance (COP) is an indicator of energy efficiency (effectiveness of cooling or heating relative to the input electricity). Higher the value, greater the energy efficiency.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereinafter, Mitsubishi Motors) and Highlanders, Inc. (hereinafter, Highlanders), a startup originating from the University of Tokyo, today announced that they have signed a Memorandum of Understanding (MOU) to collaborate in establishing a new industrial foundation where humans and robots work together. Under this MOU, the two companies will explore the joint development of humanoid robots for use at Mitsubishi Motors’ manufacturing facilities as well as mass production of Highlanders products at Mitsubishi Motors’ Kyoto Plant.The environment surrounding Japan’s manufacturing industry is undergoing significant change, with labor shortages, increasingly sophisticated manufacturing operations, and the need for more flexible manufacturing systems emerging as major challenges. Mitsubishi Motors is committed to creating new value by collaborating with a diverse range of partners, including startups, to address these future challenges. Highlanders, meanwhile, aims to help solve workforce-related issues through humanoid robots and advanced robotics technologies, with the goal of realizing a society where humans and robots collaborate seamlessly. Through this partnership, the two companies seek to create new value in manufacturing and enhance industrial competitiveness.As a first step in its joint development project with Highlanders, Mitsubishi Motors plans to utilize humanoid robots at its own manufacturing facilities. Through practical use, the company will accumulate operational data and know-how while deepening its expertise in the field of humanoid robotics and evaluating opportunities for future development and production.In parallel, Mitsubishi Motors will leverage its proven expertise in mass-production engineering, quality assurance, durability and safety design, integrated mechatronics control technologies, and factory operations to explore the production of Highlanders’ humanoid robots. The companies will examine the feasibility of commencing production in early 2027 by utilizing currently unused buildings at Mitsubishi Motors’ Kyoto Plant.This marks the first collaboration of its kind between an automotive manufacturer and a humanoid robotics developer involving mass production. By gaining an operational and manufacturing partner, Highlanders expects to accelerate the growth of both companies’ humanoid robotics businesses.Mitsubishi Motors has already invested in Highlanders and plans to make additional investments in the future.Moving forward, the two companies will continue their collaborative efforts toward realizing a society in which humans and robots work together.Comment from Takao Kato, chairman of the board, representative executive officer and CEO of Mitsubishi Motors Corporation"Our collaboration with Highlanders represents a challenge aimed at building a new industrial foundation in which humans and robots work together. At the same time, it provides Mitsubishi Motors with a valuable opportunity to deepen our technological and business expertise in the field of humanoid robotics. By utilizing humanoid robots in our own manufacturing facilities and supporting the production of Highlanders products, we aim to leverage the outcomes of this collaboration to drive our growth and enhance corporate value.”Comment from Hiroya Masuoka, representative director and CEO of Highlanders, Inc."At Highlanders, our mission is to address a wide range of industrial challenges through robotics and physical AI technologies. We believe that achieving mass production of domestically developed humanoid robots through this partnership with Mitsubishi Motors, which brings decades of manufacturing expertise, represents a significant step toward achieving this goal. Furthermore, deploying our robotics technologies within Mitsubishi Motors’ manufacturing operations will provide a valuable opportunity to drive technological advancement in our products. By maximizing the value of this collaboration, we look forward to expanding our mutually beneficial relationship with Mitsubishi Motors.” Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced that it has developed an Online Medical Certificate Integration Service, which enables online completion of insurance claim procedures for life and medical insurance. This service has been adopted by Aflac Life Insurance Japan Ltd. (Aflac Life Insurance Japan) and The Cancer Institute Hospital of JFCR (Cancer Institute Hospital). The service will commence operations at the end of August 2026.Through this service, which connects patients, medical institutions, and insurance companies, Aflac Life Insurance Japan aims to improve the convenience of insurance claim procedures for policyholders and beneficiaries, while Cancer Institute Hospital seeks to reduce the workload on medical staff involved in creating medical certificates. This initiative is part of Fujitsu's efforts to expand its Personalized Experience offering, which integrates real and digital elements to provide optimal financial services to individuals under "Uvance for Finance".BackgroundInsurance claims for life and medical insurance often require the submission of medical certificates issued by healthcare institutions. The process of creating these certificates contributes to the workload of medical professionals. Furthermore, the exchange of medical certificates has traditionally relied on in-person interactions or postal mail, which can be burdensome for both healthcare institutions and policyholders/beneficiaries. There has been a demand for a simpler and more reliable procedure that ensures security.To address these challenges, Fujitsu developed and is now offering the Online Medical Certificate Integration Service, which allows insurance claim procedures to be completed entirely online. In developing this service, Fujitsu, Aflac Life Insurance Japan, and Cancer Institute Hospital conducted a proof-of-concept from June 30, 2025, to November 30, 2025, to verify the efficiency of the medical certificate creation process, from request to receipt. The experiment confirmed benefits such as a reduction in the time required from requesting to issuing medical certificates.Service overviewThis service enables the entire process, from requesting insurance benefits to receiving medical certificates, to be completed online. Leveraging Fujitsu's expertise in electronic medical record implementation and secure network environments, the service ensures safe and reliable procedures.With this service, when a policyholder applies for insurance benefits online after receiving treatment or hospitalization, the insurance company that accepted the application determines the necessity of a medical certificate based on the application and contract details, and then informs the policyholder/beneficiary. If a medical certificate is required, the policyholder/beneficiary can make a request for the creation of a medical certificate online, a process that previously required visiting the medical institution's reception desk.Healthcare institutions can create medical certificates using the service's medical certificate creation support tool. This tool converts inpatient and outpatient data held by the medical institution into a format aligned with the insurance company's specified medical certificate items. By integrating this data into the medical institution's existing medical certificate creation support system, the tool helps streamline data entry and reduce processing time. Once the medical institution uploads the completed medical certificate to the service, both the policyholder/beneficiary and the insurance company can access it online.Figure 1: Overview of the Online Medical Certificate Integration ServiceAflac Life Insurance Japan and Cancer Institute Hospital anticipate that this service will enhance convenience for policyholders and beneficiaries by eliminating the need for hospital visits and waiting times for insurance claim procedures. Additionally, it will improve the efficiency of medical certificate creation for healthcare institutions and reduce costs and effort associated with paper-based and postal processes.Future PlansFujitsu aims to introduce this service to approximately 20 life insurance companies and 400 medical institutions by fiscal year 2031. Through this initiative, Fujitsu, while leveraging the insights gained from practical operations, will promote the advancement of business processes related to medical certificate collaboration and, by building a reliable system, contribute to creating an environment where medical professionals can focus on their core duties and enhance convenience for patients and other users of medical institutions.Furthermore, Fujitsu will advance towards a society that supports people's lives by providing seamless financial experiences through "Uvance for Finance", which enhances financial operations with data and AI.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 100,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.5 trillion yen (US$23 billion) for the fiscal year ended March 31, 2026 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 9, 2026 - (JCN Newswire via SeaPRwire.com) - JCB Co., Ltd. (JCB), Resona Holdings, Inc. (Resona) and ODAWARA AUTO-MACHINE MFG. Co., Ltd. (ODAWARA) have entered into a memorandum of understanding (MOU) to jointly develop and implement Ultra-Wideband (UWB) wireless payment solutions for public bus services.This initiative builds on the basic agreement signed on March 4, 2026, between JCB and Resona for the commercialization of UWB payments. With ODAWARA — Japan’s leading manufacturer of fare collection equipment for transit operators — joining the alliance, the three companies will accelerate the practical application of this technology in the public transportation sector.UWB is a next-generation wireless communication technology that features high-speed data transmission and highly accurate positioning capabilities. Unlike conventional contactless (NFC) or QR code payments, UWB enables completely hands-free transactions. Passengers can board and alight seamlessly without the need to tap smartphones or scan devices.Background and ObjectivesWhile global expectations for UWB applications in standard ticket gates and retail checkouts are rising, hands-free solutions for open-boarding public transportation — such as buses and streetcars without physical gates — have remained technologically challenging.Concurrently, the Japanese bus industry faces critical challenges, including driver shortages and an aging workforce. Drivers are increasingly burdened by managing diverse payment methods and assisting passengers with fare inquiries, which often causes delays during peak congestion.To address these pressing issues, JCB, Resona, and ODAWARA will launch a joint project in collaboration with active bus operators. Technical and payment verification (including precise boarding/alighting data capture) will commence in FY2026, with small-scale commercial rollouts in FY2027, aiming for full-scale commercial deployment in FY2028.RoadmapFY2026: Launch of technical trials and Proof of Concept (PoC) with bus operatorsFY2027: Initial small-scale commercial implementationFY2028: Full-scale commercial deployment and expansionAnticipated BenefitsFor Passengers (Users):Completely Hands-Free: No need to take out smartphones, wallets, or cards when boarding or exiting.Personalized Mobility Services: Real-time, location-based value delivery via smartphones or in-vehicle displays, including targeted coupons, loyalty points, transit guidance, and congested-route alerts. For Bus Operators:Operational Efficiency: Significant reduction in driver workload by eliminating manual fare handling and onboard payment troubleshooting.Enhanced Safety and Punctuality: Shorter boarding times mitigate delays, allowing drivers to focus entirely on safe driving.Data-Driven Operations: Leveraging high-precision UWB location data to visualize congestion patterns and optimize fleet scheduling.Future OutlookAs part of this strategic collaboration, ODAWARA has officially joined the FiRa® Consortium to actively promote the global standardization of UWB technology in transit payment use cases. Together with consortium partners, JCB, Resona, and ODAWARA will drive technical architecture standardization and user experience (UX) design.Looking beyond public transportation, the three companies intend to collaborate with a diverse range of domestic and international partners to expand the UWB payment ecosystem into smart retail, MaaS (Mobility as a Service), and smart city infrastructure. Corporate Profiles & Media ContactsAbout FiRa ConsortiumThe FiRa Consortium is a member-driven organization dedicated to transforming the way we interact with our environment by enabling precise location awareness for people and devices using the secured fine-ranging and positioning capabilities of Ultra-Wideband (UWB) technology. FiRa does this by driving the development of technical specifications and certification, advocating for effective regulations, and by defining a broad set of use cases for UWB. To learn more about UWB and the FiRa Consortium, visit: www.firaconsortium.org.About ODAWARA AUTO-MACHINE MFG. Co., Ltd.Guided by our corporate motto, “Serving society with a pioneering spirit,” we specialize in fare collection equipment for public transportation, such as local buses. By delivering innovative products, services, and digital transformation (DX) solutions, we aim to improve the sustainability of public transportation and revitalize local communities.For more information, please visit: https://www.odawarakiki.com/ About Resona Holdings, Inc.With the Group's purpose of "Beyond Finance, for a Brighter Future." we continue to take on the challenge of transformation and creation in order to transform the future into a positive one with ideas that go beyond the framework of finance. Adhering to our basic stance of "customer joy is Resona's joy," we will work to "strengthen value creativity" and "next-generation management infrastructure" to respond to customers and local communities.For more information, please visit: https://www.resona-gr.co.jp/holdings/english/About JCB Co., Ltd.JCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 72 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 181 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide.For more information, please visit: www.global.jcb/en/Media ContactsJCB Corporate Communications Anna TakedaTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jpODAWARA AUTO-MACHINE MFG. Co., Ltd. Email: contact_NBPD@odawarakiki.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 6, 2026 - (JCN Newswire via SeaPRwire.com) - JCB Co., Ltd. (Headquarters: Minato-ku, Tokyo; Chairman & Chief Executive Officer: Takayoshi Futae; hereinafter: JCB), Japan’s only international payment brand, and MUFG Bank, Ltd. (President & CEO: Masakazu Osawa), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (President & Group CEO: Junichi Hanzawa; hereinafter "MUFG"), have entered into a Memorandum of Understanding (MOU) regarding a comprehensive strategic alliance in the ASEAN region.This alliance aims to leverage our complementary strengths by utilizing both companies’ customer bases and financial and payment networks to jointly drive business expansion and create new value across ASEAN.Purpose and Background of the AllianceIn ASEAN, sustained economic growth is driving the expansion of the affluent segment, alongside the growing adoption of digital payments. As a result, demand for financial and payment services is becoming increasingly sophisticated and diverse.In this context, MUFG Bank’s partner bank network, investments in digital businesses, and financial infrastructure will be combined with JCB’s global payment network, Japan’s largest merchant network, and extensive service expertise. By integrating these capabilities with financial services, such as deposits and investments, the two companies aim to create new value, particularly in affluent customer segments and digital payment areas.Key Areas of CollaborationStrengthening Financial Services for Affluent Customers in ASEANLeveraging partnerships with MUFG’s partner banks, we will offer card products that provide exclusive and unique experiences and benefits in Japan for affluent customers in ASEAN. In addition, by linking these card products with financial services, such as deposits and investments, we will deliver enhanced value. As an initial initiative in fiscal year 2026 (ending March 2027), we plan to issue a new premium card in Indonesia, which will be JCB’s highest-tier card ever issued outside Japan.Expansion of Collaboration in the ASEAN Payment DomainBoth companies will explore collaboration between MUFG’s investees in the digital finance sector and JCB’s payment capabilities. Through these efforts, we will consider expanding cross-border payment solutions and mobile services, with the aim of accelerating the development of digital payment ecosystems in ASEAN.By combining their customer bases and payment expertise, the two companies will promote the advancement of financial services and create new business opportunities and synergies.Building Partnerships with Japanese Companies and Promoting Japan as a Tourism-Oriented NationThis alliance aims to establish and expand a “Japan-led financial and payment partnership platform” centered on MUFG Bank and JCB in ASEAN. Building on this foundation, we will broaden partnerships not only with partner banks and digital financial players but also with a wide range of Japanese companies, thereby enhancing the global reach of Japanese brands and services.Beyond financial and payment services, the alliance will drive new business creation through collaboration with Japanese companies and contribute to strengthening Japan’s presence in ASEAN.Through these initiatives, both companies aim to help build a new economic sphere connecting ASEAN and Japan, while supporting efforts to further position Japan as a leading tourism destination.Branding ImageFuture DevelopmentsBased on this MOU, both companies will move forward with concrete initiatives. Leveraging this alliance, we will further expand partnerships with Japanese companies and strive to achieve sustainable growth and create new value in ASEAN.About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 72 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 181 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

JAKARTA, July 4, 2026 - (ACN Newswire via SeaPRwire.com) - Siloam International Hospitals has again been recognised at the highest level with two of its hospitals receiving Magnet® with Distinction Recognition. Siloam Hospitals Kebon Jeruk became the first hospital in Indonesia to receive the recognition on 23 June 2026, followed by Siloam Hospitals Lippo Village on 26 June 2026. With this achievement, Siloam has become the only hospital network in Southeast Asia with more than one hospital recognised as Magnet® with Distinction. To date, only 95 healthcare organisations worldwide have achieved Magnet® with Distinction, placing Siloam among the world's leading healthcare organisations in nursing excellence while reinforcing Indonesia's position as one of the few countries with hospitals recognised for world-class nursing standards.Magnet Recognition® is the gold standard for nursing excellence awarded by the American Nurses Credentialing Center (ANCC), the world's largest nursing credentialing organization and a subsidiary of the American Nurses Association (ANA). Magnet® with Distinction is the highest level of recognition, introduced by the ANCC in 2022 to honour top-performing healthcare organisations based on validated empirical outcomes. The designation is awarded only to organisations that demonstrate clinical outcomes, quality of care and nursing performance that exceed the already rigorous Magnet® standards.For patients, healthcare quality is determined not only by advanced technology and skilled physicians, but also by the quality of nursing care that supports them throughout their treatment journey. Studies show that Magnet® hospitals achieve better patient safety outcomes, lower complication rates, stronger interdisciplinary collaboration, and more positive patient experiences than non-Magnet® hospitals.These outcomes are reflected in the performance of Siloam Hospitals Kebon Jeruk and Siloam Hospitals Lippo Village, which recorded nurse satisfaction rates of 93% and 95%, respectively, while 70% and 73% of their nursing workforce hold professional specialty certifications. Both hospitals also demonstrated nursing quality indicators that exceeded international benchmarks, including reductions in healthcare-associated infections (CAUTI and CLABSI), hospital-acquired pressure injuries (HAPI), as well as improvements in patient experience across communication, respect for patients, shared decision-making, and care coordination.Caroline Riady, CEO of Siloam International Hospitals, said the achievement recognises the dedication of Siloam nurses who deliver exceptional care to patients every day.“Magnet® with Distinction is more than an institutional recognition. It reflects the commitment of Siloam nurses who stand beside patients and their families throughout every stage of the care journey. At Siloam, we believe that the combination of clinical excellence and compassionate care forms the foundation of high-quality healthcare. When patients feel heard, undertood, and cared for with empathy, it can have a meaningful impact on both their experience and clinical outcomes. Ultimately, healthcare quality is measured not only by the technology and facilities a hospital possesses, but also by the people who are there for patients when they need them the most," said Caroline.Jessi Rahardja, Nursing General Manager of Siloam International Hospitals, explained that the journey towards achieving Magnet Recognition® requires a sustained commitment to strengthening evidence-based nursing practice, fostering a collaborative culture, and delivering patient-centered care."For us, Magnet® is more than external recognition. It is proof that nursing is a profession grounded in evidence, leadership, and collaboration, with a tangible impact on patient outcomes. Patients experience these benefits through more consistent care, stronger coordination, and an overall better care experience. To every Siloam nurse, this achievement is truly historic. Yet it is not the pinnacle of what you are capable of—it is a reflection of the dedication and professionalism you demonstrate every day in caring for patients," said Jessi.The success of Siloam Hospitals Kebon Jeruk and Siloam Hospitals Lippo Village is the result of Siloam's long-term investment in the development of the nursing profession and healthcare workforce. In line with its People First pillar, Siloam has built an integrated education ecosystem through the Faculty of Medicine and Nursing at Universitas Pelita Harapan, the Siloam Training Center, and a wide range of continuous professional development programs that strengthen clinical competencies, leadership capabilities, and evidence-based practice.Looking ahead, Siloam will continue to strengthen a culture of nursing excellence across its hospital network as part of its commitment to delivering internationally benchmarked healthcare services for the people of Indonesia. This commitment seeks to support better clinical outcomes while ensuring that more Indonesians have access to world-class care within the country, without needing to seek treatment overseas. Ultimately, healthcare excellence is defined not only by technology and infrastructure, but also by the quality of the people who stand beside patients every day.For more information, please contact:Corporate Communicationcorcomm@siloamhospitals.comTo read more, please visit www.siloamhospitals.com.More on the Magnet® Recognition Program and Magnet® with Distinction(TM): https://www.nursingworld.org/organizational-programs/magnet/new-magnet-organizations/ About Siloam International HospitalsPT Siloam International Hospitals Tbk (“Siloam”) is a leading private hospital network committed to providing high-quality healthcare services in Indonesia. Established in 1996, the Siloam currently manages and operates 41 hospitals, including 15 hospitals in the Greater Jakarta area (Jabodetabek) and 26 hospitals across Java, Sumatra, Kalimantan, Sulawesi, Bali, Nusa Tenggara and Ambon. In addition, the Siloam Hospitals also operates 75 Siloam Clinic units to maximize healthcare access for all Indonesians. Founded on God’s compassion, Siloam has a vision to provide international quality healthcare services accessible to all levels of society in Indonesia. In line with this vision, Siloam has also become a trusted choice in delivering world-class holistic healthcare, as well as continuous medical education and research. Supported by a medical team consisting of more than 2,000 general practitioners and specialists, and 10,000 nurses and professional staff, Siloam’s medical team works tirelessly to provide the best care, serving nearly two million patients annually across Indonesia. Siloam is a pioneer in achieving Joint Commission International (JCI) accreditation for hospitals in Indonesia. JCI is an international accreditation agency based in the United States that focuses on setting the highest standards for healthcare service quality and patient safety. In 2025, Siloam received international recognition from Newsweek as one of the World’s Most Trustworthy Companies 2025. Siloam also achieved a Silver Medal from EcoVadis with a score of 71, reflecting a 7-point increase from the previous year. This achievement places Siloam among the top 15% of companies globally for Environmental, Social, and Governance (ESG) performance, out of more than 130,000 companies assessed. Within the Human Health Activities sector, Siloam ranks in the top 3% globally, demonstrating its consistent commitment to responsible and sustainable healthcare delivery. The company also achieved strong performance across all ESG pillars, including top 5% for Environment, top 10% for Labor & Human Rights, top 12% for Ethics, and top 1% for Sustainable Procurement.In 2026, Siloam International Hospitals received several international recognitions that reinforce its leadership in delivering world-class healthcare. At the Healthcare Asia Awards 2026, Siloam received four prestigious awards: Hospital Group of the Year – Indonesia and Service Delivery Innovation of the Year – Indonesia for Siloam International Hospitals; Specialty Hospital of the Year (Cardiology) – Indonesia for Siloam Heart Hospital; and Medical Tourism Hospital of the Year – Indonesia for Bali International Medical Center (BIMC) Siloam Nusa Dua.This commitment to excellence was also reflected in the achievement of Magnet® with Distinction by Siloam Hospitals Kebon Jeruk and Siloam Hospitals Lippo Village. With this milestone, Siloam became the only hospital network in Southeast Asia with more than one hospital recognised under the Magnet Recognition Program®.These international recognitions underscore Siloam’s consistency in delivering integrated, innovative, safe, and internationally benchmarked healthcare services, while reinforcing its role as a leader in transforming healthcare in Indonesia.For more information, please visit www.siloamhospitals.com.More on the Magnet® Recognition Program and Magnet® with Distinction:https://www.nursingworld.org/organizational-programs/magnet/new-magnet-organizations/ Disclaimer: This Press Release is prepared by Siloam Hospitals and is distributed only to convey general information. This Press Release is not intended for a particular group or purpose and does not constitute a recommendation regarding the shares of Siloam Hospitals. No guarantee is given regarding the completeness or certainty of the information contained. All opinions and estimates included in this Press Release are our opinions as of this date and are subject to change without notice. Siloam Hospitals is not responsible for any losses that may occur to any party due to part or all the contents of this Press Release, Siloam Hospitals and affiliated companies including their employees and agents are not responsible for any mistakes, omissions, or inaccuracies that can happen. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Contract Signing CeremonyTOKYO, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has signed a contract with Taiwan High Speed Rail Corporation (THSRC), the operator of the Taiwan High Speed Rail (THSR) network, for maintenance tools and equipment for the Yanchao Main Workshop in southern Taiwan. The Yanchao Main Workshop is a facility for maintenance and inspection of trains owned by THSRC. For this project, MHI will deliver, install, and conduct testing and commissioning of maintenance tools and equipment for the Yanchao Main Workshop.THSRC is currently introducing the new N700ST series trains, with commercial operation scheduled to begin in the second half of 2027. This project aims to strengthen the maintenance system in line with the introduction of the new N700ST series trains, contributing to further improvements in the THSR network's transportation services.Since its inauguration in 2007, the THSR network has been widely utilized as core transportation infrastructure in Taiwan. Annual ridership has increased significantly from about 15 million at the time of opening to approximately 82 million in 2025. Currently, the network serves an average of approximately 230,000 passengers per day, and its cumulative ridership has surpassed 1 billion, playing a vital role in supporting economic activity and mobility in Taiwan.The THSR Core System Supply Contract was awarded in 2000 to a consortium of seven Japanese companies, including MHI, and commercial operations commenced in January 2007. Since the inauguration, MHI has contributed to the development of the THSR network through involvement in such projects as the Nangang Extension Project and the Trackwork and Core System for the Zuoying Depot. This project reflects recognition of MHI's longstanding track record and technical expertise.Going forward, MHI will continue to leverage its technology and expertise in transportation systems and project management capabilities to contribute to the further development of the THSR network, and the realization of safe and reliable service.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit: www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

NEW YORK, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi Rail has successfully completed the acquisition of Clever Devices, a leading U.S.-based provider of Intelligent Transportation Systems for transit agencies around the world.Clever Devices is recognized for its pioneering technology solutions that enhance fleet management, passenger experience and operational efficiency for mass transit agencies. The company has offices across the United States, Europe and South America.The acquisition of a company with deep digital expertise and projected 2026 revenues of over $220 million enables Hitachi Rail to reflect the increasing demand for more integrated transportation systems. With completion of the transaction, Hitachi Rail extends its footprint beyond rail into multimodal mobility and further strengthens its presence in North America.With over 600 employees and a customer base that includes 8 of the 10 largest North American transit agencies, Clever Devices has a strong track record of innovation and delivery. Its Intelligent Transport System (ITS) solutions are a critical enabler of increased public transport usage, improving the accuracy of information and boosting service punctuality. These solutions are deployed across public mobility systems, including buses as well as railways. In addition to its strong North American presence, Clever Devices has achieved substantial growth in markets such as Brazil and Chile, as well as in Europe, including Italy.Clever Devices portfolio of onboard and centralised data solutions augments Hitachi's HMAX Mobility suite of physical AI solutions, bringing enhanced functionality and benefits for customers across public transport systems globally.HMAX for Rail sits as part of HMAX Mobility ​ and is Hitachi Rail's digital asset management platform that optimizes railway performance by connecting data from fleets of trains, signalling assets and infrastructure to create an operational twin of rail systems. It combines advanced sensor technology, rail expertise, AI and edge computing to maximize performance, extend asset life and optimize costs.Giuseppe Marino, Group CEO, Hitachi Rail, said:​"This is a key step in advancing our strategy to drive the digital transformation of public transport. We are combining Clever Devices' strong capabilities in intelligent transportation systems with our global reach and HMAX Mobility suite of solutions. With this acquisition, we are broadening our scope beyond rail, strengthening our footprint in North America, and laying the platform to help cities develop more integrated, sustainable and efficient transportation networks."As part of the integration, where he led the launch of Hitachi's Industrial AI portfolio. As CEO, Frank will focus on accelerating growth, strengthening market positioning and driving long-term value creation for the Clever Devices business.Frank Antonysamy, CEO, Clever Devices, a Hitachi Group Company, said:​"Joining Clever Devices at this important moment is a great opportunity. As part of Hitachi Rail, we are well positioned to leverage Hitachi's investments in HMAX and more than 115 years of OT expertise, to accelerate innovation, expand our global reach and deliver enhanced value to transit agencies and passengers through our advanced digital mobility solutions"Hitachi Rail's growing footprint in North America is underlined by recent investments including the $110m opening of its digital factory in Hagerstown, Maryland, and a CA$30m investment in a new Canadian headquarters.Hitachi Rail collaborated with SSIB, Hitachi's Strategic Social Innovation Business Unit, on the acquisition, supporting the One Hitachi initiative and creating further opportunities across the mobility sector. The business will also benefit from the wider digital expertise of Hitachi Group companies, including Hitachi Digital, GlobalLogic and Hitachi Digital Services.About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi aims to be a global leader in continuously transforming social infrastructure through digital , contributing to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates worldwide across four sectors - Digital Systems & Services, Energy, Mobility, and Connective Industries - as well as a Strategic SIB Business Unit focused on new growth areas . With Lumada at its core, Hitachi creates value by combining data, technology and domain knowledge to solve customer and social challenges. Revenues for FY 202 5 (ended March 31, 202 6 ) totaled 10,586 .7 billion yen, with 6 06 consolidated subsidiaries and approximately 2 9 0,000 employees worldwide. Visit us at www.hitachi.com .About Hitachi RailHitachi Rail is committed to driving the transition to sustainable mobility and has a clear focus on partnering with customers to rethink mobility. Its mission is to help every passenger, customer, and community enjoy the benefits of more connected, smooth, and sustainable transportation. With a turnover of more than €7 billion and 24,000 employees in more than 50 countries, Hitachi Rail is a reliable partner for the world's best transport companies. The company's presence is global, but the company is local, with success based on developing local talent and investing in people and communities. Its international expertise and experience covers every part of urban ecosystems, main lines and freight railways, from high - quality production and maintenance of rolling stock to digital signaling, payment systems and smart operations. Hitachi Rail, famous for Japan's iconic high -speed train, leverages the digital and artificial intelligence expertise of Hitachi Group companies to accelerate innovation and develop new technologies. For more information, visit hitachirail.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer’s disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer’s Association International Conference® 2026 (AAIC®) from July 12-15 in London and online. Eisai will present 52 abstracts across its AD portfolio at AAIC. Highlights include a Developing Topics Session and a Featured Research Session on lecanemab, featuring four and six oral presentations, respectively, alongside 10 additional key oral presentations and 32 posters. Eisai will also host a symposium on early intervention in AD.​Key PresentationsA Developing Topics Session will feature emerging clinical evidence and practical use considerations for the subcutaneous formulation of lecanemab, including clinical trial and real-world patient experience. A Featured Research Session will highlight data from the LEADER study evaluating real-world lecanemab use in diverse US clinical settings three years post-approval, including results on maintenance dosing with IV treatment every four weeks and the first reported findings of at-home subcutaneous administration.Presentations on the Phase 3 AHEAD 3-45 study in preclinical AD will highlight progress of the trial including updates on participant retention and engagement.Additional oral presentations will highlight a Phase 2 trial of etalanetug with background lecanemab, and the effect on tau pathology.“We are sharing a broad and robust data set at AAIC spanning the Alzheimer’s disease continuum, multiple therapeutic targets, and modes of administration, underscoring our commitment to advancing care for this complex disease,” said Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. “Growing real-world experience with lecanemab, along with insights from patients, care partners, and clinicians, continues to add to our understanding of the value of early intervention, long-term treatment, and patient choice in care delivery.”AAIC 2026 Presentations Relating to Eisai's Key Compounds and ResearchDeveloping Topics Session #1-32-FRS-C: Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations4:15-5:45 PM BST, Sunday, July 12Session ProgramOverview of Lecanemab Subcutaneous Formulation in Early Alzheimer’s DiseaseSafety Profile of a Subcutaneous Lecanemab FormulationClinical Outcomes and Patient Experience of Subcutaneous Lecanemab Administration from an Alzheimer's Disease Treatment CenterReal-World Patient-Reported Outcomes with Subcutaneous Lecanemab Treatment in Early Alzheimer's Disease in the United States: A Case SeriesFeatured Research Session #4-33-FRS-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings4:15-5:45 PM BST, Tuesday, July 14Session ProgramA Three-year Update of Lecanemab in Early Alzheimer’s Disease: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER)Lecanemab Use and Clinical Outcomes by APOE ε4 Status, Concomitant Medications, Sex, Race, and Ethnicity: Findings from the LEADER StudyReal-World Use of Lecanemab Once-Monthly Maintenance Dosing in Early Alzheimer’s Disease: A Multicenter, Retrospective US StudyThe First Reported Findings of At-Home Subcutaneous Lecanemab Administration: A Real-World, Multicenter, Retrospective StudyReal-World Insights on Lecanemab Maintenance Therapy Patient Pathway From A Multicenter, Real-World, Retrospective Study (LEADER)Physician and Perceived Patient Satisfaction with Lecanemab Maintenance Therapy: An Update from the LEADER StudyAdditional Oral Presentations Asset / Topic, Presentation Date and Time (BST)Presentation TitleLecanemabJuly 12 (Sun.)2:00 – 3:30 PMDeveloping Topics Session 1-23-FRS-B: Developing Topics in Amyloid Targeting Therapies: Global Perspectives from Trials to Real World EvidencePresentation: Treatment Actions following ARIA in Patients Treated with Lecanemab: Evidence from a Post-Marketing Observational Study in Japan (Abstract ID TBA)LecanemabJuly 13 (Mon.)8:00 – 8:45 AMDeveloping Topic Session #2-6-DEV: Developing Topics in Amyloid Targeting Therapies and Real-World OutcomesPresentation: Sex-Based Outcomes of Lecanemab in Early Alzheimer’s Disease: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) (Abstract ID TBA)LecanemabJuly 13 (Mon.)9:00 – 10:30 AMFeatured Research Session #2-15-FRS-A: External Controls In Alzheimer’s Clinical Trials: How Far Away Are We?Presentation: External Controls in Open-Label Extensions: Insights from Clarity AD (Abstract ID 982)LecanemabJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's DiseasePresentation: Broad Modulation of Core Tau Biomarkers, Including pTau205 Following Lecanemab Treatment (Abstract ID 13515)LecanemabJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's DiseasePresentation: Tau PET Change in CLARITY-AD (Abstract ID 13333)LecanemabJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-3-DEV: Developing Topics in Factors Affecting Fluid BiomarkersPresentation: Racial And Ethnic Differences in %p-tau217 Associations with Cognitive Performance and Amyloid PET In Preclinical AD (Abstract ID 13712)LecanemabJuly 14 (Tues.)9:00 – 10:30 AMFeatured Research Session #3-15-FRS-A: Anti-Amyloid Therapy: Real World ExperiencePresentation: Lecanemab Clinical Practice: A Multicenter, Surveillance Safety Study from the ALZ-NET Registry (Abstract ID 6202)Etalanetug (E2814)July 13 (Mon.)9:00 – 10:30 AMFeatured Research Session #2-17-FRS-A: Alzheimer's Therapy: Mechanisms Beyond AmyloidPresentation: Baseline Imaging Characteristics of Participants in a Phase 2 Trial of Etalanetug and Concurrent Lecanemab (Abstract ID 10449)Etalanetug (E2814)July 13 (Mon.)9:00 – 10:30 AMFeatured Research Session #2-17-FRS-A: Alzheimer's Therapy: Mechanisms Beyond AmyloidPresentation: Etalanetug and Tau Tangle Specific Plasma eMTBR-tau243 in DIAD (Abstract ID 9850)BiomarkersJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-3-DEV: Developing Topics in Factors Affecting Fluid BiomarkersPresentation: Refining Plasma pTau217/Aβ42 Cutoffs for Amyloid Positivity in an Asian Cohort with High Cerebrovascular Disease Burden (Abstract ID TBA)Poster PresentationsAsset / Topic, Presentation Date**Title, Abstract NumberLecanemabJuly 12 (Sun.)Characterization and Utilization Assessment of a Centrally Supported Ride-Share Service Implemented in a Multisite Preclinical Alzheimer’s Clinical Trial (Abstract ID TBA)LecanemabJuly 12 (Sun.)Long-Term Persistence and Patient Characteristics for Intravenous and Subcutaneous Lecanemab in Real-World Use in the United States (Abstract ID 7344)LecanemabJuly 12 (Sun.)Retrospective Case Series of Real-world Clinical and Patient-reported Outcomes with Lecanemab (Abstract ID 9480)LecanemabJuly 12 (Sun.)Retrospective Observational Cohort Study of Real-world Clinical and Patient-reported Outcomes with Lecanemab (Abstract ID 9882)LecanemabJuly 13 (Mon.)Subcutaneous Lecanemab Administration in an Alzheimer’s Disease Treatment Center: Real-World Clinical Outcomes and Patient Experiences (Abstract ID 1556)LecanemabJuly 13 (Mon.)INITIATE-SC: A Multicenter Real-World Study of Subcutaneous Lecanemab Initiation in Early Alzheimer’s Disease (Abstract ID 13568)LecanemabJuly 13 (Mon.)Continued or Time-limited Treatment Benefits of Anti-amyloid Monoclonal Antibodies In Early Alzheimer’s Disease (Abstract ID 13738)LecanemabJuly 13 (Mon.)Early Alzheimer’s Disease Treated with Lecanemab: A Real-World, Retrospective Analysis from a Colorado Neurological Clinic (Abstract ID 12904)LecanemabJuly 13 (Mon.)Communicating Participant Milestones to Enhance Trial Engagement and Retention in a Preclinical Alzheimer’s Trial (Abstract ID 9159)LecanemabJuly 13 (Mon.)Initial Real-World Experience in Using Lecanemab in Hong Kong: Safety and Preliminary PET CT Data (Abstract ID 11962)LecanemabJuly 14 (Tues.)Real-World Lecanemab Treatment in Early Alzheimer’s Disease: A Retrospective Dementia Clinic Case Series Review from a Geriatric Medicine Clinical Practice (Abstract ID 1947)LecanemabJuly 15 (Weds.)A Time and Motion and Patient Satisfaction Study of Subcutaneous Injection of Lecanemab for Patients with Early Alzheimer’s Disease (Abstract ID 13637)LecanemabJuly 15 (Weds.)Differential Costs Of Amyloid-related Imaging Abnormality Management Between Anti-amyloid Treatments: Estimates Based On A Delphi Panel (Abstract ID 9345)LecanemabJuly 15 (Weds.)VISION AD-JP: A Prospective Multicenter Real-world Study of Japanese Patients with Early Alzheimer’s Disease Treated with Lecanemab (Abstract ID 13235)LecanemabJuly 15 (Weds.)Real-World Outcomes with Lecanemab Treatment in a New England Alzheimer’s Disease Center (Abstract ID 1949)LecanemabJuly 15 (Weds.)Estimating the Economic Impact of Delayed Alzheimer's Disease Progression with Lecanemab (Abstract ID 9889)LecanemabJuly 15 (Weds.)Economic, Health, and Quality-of-Life Burden on Caregivers and Study Partners of Lecanemab-Treated Individuals with Alzheimer’s Disease (Abstract ID 6169)Etalanetug (E2814)July 13 (Mon.)A Surrogate Antibody Of Etalanetug, H25L15-hIgG1, and Uptake Of Tau Monomer And Aggregate In Human Macrophages Through Fcγ Receptors (Abstract ID 11847)Etalanetug (E2814)July 14 (Tues.)A Novel CSF eMTBR-tau243 Immunoassay for Detecting AD Tau Pathology and Assessing Etalanetug Pharmacodynamics in DIAD (Abstract ID 6867)BiomarkersJuly 12 (Sun.)Blood-Based Biomarkers in Early Alzheimer’s Disease: Real-World Adoption Trends and Diagnostic Pathways (Abstract ID 13215)BiomarkersJuly 12 (Sun.)From First Visit to Disclosure: Confirmatory Blood-Based Biomarkers and Diagnostic Timing in Alzheimer’s Disease (Abstract ID 13219)BiomarkersJuly 12 (Sun.)Practical Factors Influencing the Use of Confirmatory Blood-Based Biomarkers in Alzheimer’s Care (Abstract ID 132220)BiomarkersJuly 12 (Sun.)Frontline Perspectives on the Real-World Use of Blood-Based Biomarkers in Alzheimer’s Disease (Abstract ID 13480)BiomarkersJuly 13 (Mon.)Evolution of Real-World Blood-Based Biomarker Use in the Lecanemab Patient Pathway: Three-Year Update From the LEADER Study (Abstract ID 13216)BiomarkersJuly 13 (Mon.)Retrospective Analysis of Costs of Amyloid Diagnostic Tests for Alzheimer’s Disease from a Health-system Perspective (Abstract ID 6663)BiomarkersJuly 13 (Mon.)Piloting Digital Cognitive Assessments and a Blood-Based Biomarker to Improve Alzheimer’s Disease Diagnosis (Abstract ID 3554)BiomarkersJuly 13 (Mon.)Real-World Diagnostic Pathways For Alzheimer’s Disease In U.S. Clinical Practice Using Claims And Integrated EHR Data (Abstract 13436)BiomarkersJuly 15 (Weds.)Integrated Peptide-Level Global Proteomics and Co-expression Network Analysis: Insights into Amyloid-beta-Driven Dementia (Abstract ID 10170)Biomarkers (non-clinical)July 12 (Sun.)Proteomic Assessment of CSF Biomarkers of Neurodegeneration from a Minimally Invasive and Serial CSF Collection Technique in Mice (Abstract ID 2306)General ADJuly 13 (Mon.)Could Driving Time to Infusion Sites be an Obstacle to Receiving Alzheimer’s Treatments? (Abstract ID 2151)General ADJuly 13 (Mon.)Treatment Goals for Anti-Amyloid Therapy (AAT) in Early-AD: A Consensus from U.S. Dementia Specialists (Abstract ID 13578)General ADJuly 14 (Tues.)From Feasibility to Real-World Readiness: Interpreting Evidence for Self-Administered Digital Cognitive Assessments (Abstract ID 10780)**Poster viewing time is set from 7:30 AM – 4:15 PM BST on the date of presentationEisai-Sponsored Symposium***Symposium is intended for HCPs onlyAsset / Presentation Date and Time (BST)TitleLecanemabJuly 14 (Tues.)12:30 – 1:45 PMEarly Intervention in Alzheimer’s Disease: Building the Evidence from Pathology to PracticeEisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.MEDIA CONTACTSPublic Relations DepartmentEisai Co., Ltd.TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 7739-600-678EMEA-comms@eisai.netEisai Inc. (U.S.)Julie Edelman+1-862-213-5915Julie Edelman@eisai.comAbout lecanemab (generic name, brand name: LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026 and granted Priority Review. The sBLA has been assigned an extended Prescription Drug User Fee Act (PDUFA) action date of August 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilsProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2About etalanetug (E2814)Etalanetug is an anti-MTBR (microtubule-binding region) tau antibody discovered through collaborative research between Eisai and University College London. It is designed to inhibit the propagation of tau seeds within the brain. Etalanetug is being developed as a potential disease-modifying therapy for tauopathies, including sporadic Alzheimer's disease (AD).Currently, etalanetug is being evaluated in two ongoing clinical studies: the Tau NexGen Phase 2/3 trial in dominantly inherited Alzheimer's disease (DIAD), conducted under the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) and led by Washington University School of Medicine in St. Louis, added to the standard-of-care anti-Aβ protofibril antibody lecanemab (brand name: LEQEMBI), and the Phase 2 Study 202, a global randomized trial in individuals with early sporadic AD, also assessing etalanetug added to lecanemab. In September 2025, etalanetug received Fast Track designation from the U.S. Food and Drug Administration (FDA).About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com